Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma

References

• WHO . GLOBOCAN 2020 estimated cancer incidence, mortality and prevalence worldwide. http://globocan.iarc.fr/ (Accessed 28November2023).
   Google Scholar
• Thrift AP . The epidemic of oesophageal carcinoma: where are we now?Cancer Epidemiol.41, 88–95 (2016).
   PubMed Web of Science ®Google Scholar
• Devesa SS , BlotWJ , FraumeniJFJr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer83, 2049–2053 (1998).
   PubMed Web of Science ®Google Scholar
• Gholipour C , ShalchiRA , AbbasiM. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis. Esophagus21, 322 (2008).
   PubMed Web of Science ®Google Scholar
• Abnet CC , ArnoldM , WeiWQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology154, 360 (2018).
   PubMed Web of Science ®Google Scholar
• Engel LS , ChowWH , VaughanTL , GammonMD , RischHA , StanfordJLet al. Population attributable risks of esophageal and gastric cancers. J. Natl Cancer Inst.95, 1404 (2003).
   PubMed Web of Science ®Google Scholar
• Ajani JA , D’AmicoTA , BentremDJet al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw.21, 393–422 (2023).
   PubMedGoogle Scholar
• Kitagawa Y , IshiharaR , IshikawaHet al. Esophageal Cancer Practice Guidelines 2022 edited by the Japan Esophageal Society: part 1. Esophagus1–30 doi: 10.1007/s10388-023-00993-2 (2023) ( Epub ahead of print).
   PubMedGoogle Scholar
• Njei B , McCartyTR , BirkJW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J. Gastroenterol. Hepatol.31, 1141–1146 (2016).
   PubMed Web of Science ®Google Scholar
• Rustgi AK , El-SeragHB. Esophageal carcinoma. N. Engl. J. Med.371, 2499–2509 (2014).
   PubMed Web of Science ®Google Scholar
• Iizuka T , KakegawaT , IdeHet al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group tial. Jpn J. Clin. Oncol.22, 172–176 (1992).
   PubMed Web of Science ®Google Scholar
• Hayashi K , AndoN , WatanabeHet al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J. Clin. Oncol.31, 419–423 (2001).
   PubMed Web of Science ®Google Scholar
• Hiramoto S , KatoK , ShojiHet al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. J. Clin. Oncol.23, 466–472 (2018).
   Web of Science ®Google Scholar
• Bleiberg H , ConroyT , PaillotBet al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer33, 1216–1220 (1997).
   PubMed Web of Science ®Google Scholar
• Adenis A , BennounaJ , EtiennePLet al. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: a randomised phase II trial (E-DIS). Eur. J. Cancer111, 12–20 (2019).
   PubMed Web of Science ®Google Scholar
• Kato K , TaharaM , HironakaSet al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother. Pharmacol.67, 1265–1272 (2011).
   PubMed Web of Science ®Google Scholar
• Muro K , HamaguchiT , OhtsuAet al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol.15, 955–959 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto S , KawakamiH , KiiTet al. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. Eur. J. Cancer154, 307–315 (2021).
   PubMed Web of Science ®Google Scholar
• Burkart C , BokemeyerC , KlumpBet al. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res.27, 2845–2848 (2007).
   PubMed Web of Science ®Google Scholar
• Okada M , KijimaT , AoeKet al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin. Cancer Res.25, 5485–5492 (2019).
   PubMed Web of Science ®Google Scholar
• Wang C , ThudiumKB , HanMet al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res.2, 846–856 (2014).
   PubMed Web of Science ®Google Scholar
• Wolchok JD , Chiarion-SileniV , GonzalezRet al. Melanoma overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med.377, 1345–1356 (2017).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , Paz-AresL , BernabeCaro Ret al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med.381, 2020–2031 (2019).
   PubMed Web of Science ®Google Scholar
• Baas P , ScherpereelA , NowakAKet al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet397, 375–386 (2021).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB , McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373, 1803–1813 (2015).
   PubMed Web of Science ®Google Scholar
• Armand P , EngertA , YounesAet al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J. Clin. Oncol.36, 1428–1439 (2018).
   PubMed Web of Science ®Google Scholar
• Harrington KJ , FerrisRL , BlumenscheinGJret al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol.18, 1104–1115 (2017).
   PubMed Web of Science ®Google Scholar
• Yamamoto N , NokiharaH , YamadaYet al. Phase I study of nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest. New Drugs35, 207–216 (2017).
   PubMed Web of Science ®Google Scholar
• Yokosuka T , TakamatuM , Kobayashi-ImanishiWet al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med.209, 1201–1217 (2012).
   PubMed Web of Science ®Google Scholar
• Hui E , CheungJ , ZhuJet al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediate inhibition. Science355, 1428–1433 (2017).
   PubMed Web of Science ®Google Scholar
• Wei SC , DuffyCR , AllisonJP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov.8, 1069–1086 (2018).
   PubMed Web of Science ®Google Scholar
• Centanni M , MoesDJAR , TrocónizIF , CiccoliniJ , van HasseltJGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin. Pharmacokinet.58, 835–857 (2019).
   PubMed Web of Science ®Google Scholar
• Agrawal S , FengY , RoyA , KolliaG , LestiniB. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J. Immunother. Cancer4, 72 (2016).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , DrakeCG , WollnerIet al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28, 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366, 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Long GV , TykodiSS , SchneiderJGet al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann. Oncol.29, 2208–2213 (2018).
   PubMed Web of Science ®Google Scholar
• Kudo T , HamamotoY , KatoKet al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet. Oncol.18, 631–639 (2017).
   PubMed Web of Science ®Google Scholar
• Doki Y , AjaniJA , KatoKet al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med.386, 449–462 (2022).
   PubMed Web of Science ®Google Scholar
• Kelly RJ , AjaniJA , KuzdzalJet al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med.384, 1191–1203 (2021).
   PubMed Web of Science ®Google Scholar
• Sun JM , ShenL , ShahMAet al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet398, 759–771 (2021).
   PubMed Web of Science ®Google Scholar
• Luo H , LuJ , BaiYet al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA326, 916–925 (2021).
   PubMed Web of Science ®Google Scholar
• Wang ZX , CuiC , YaoJ , ZhangYet al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell40, 277–288 (2022).
   PubMed Web of Science ®Google Scholar
• Lu Z , WangJ , ShuYet al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ.377, e068714 (2022).
   PubMedGoogle Scholar
• Xu J , KatoK , RaymondEet al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol.24, 483–495 (2023).
   PubMed Web of Science ®Google Scholar
• Kato K , ChoBC , TakahashiMet al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol.20, 1506–1517 (2019).
   PubMed Web of Science ®Google Scholar
• Kojima T , MuroK , FrancoisEet al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J. Clin. Oncol.38, 4138 (2020).
   PubMed Web of Science ®Google Scholar
• Huang J , XuJ , ChenY , ZhuangWet al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol.21, 832–842 (2020).
   PubMed Web of Science ®Google Scholar
• Shen L , KatoK , KimSBet al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J. Clin. Oncol.40, 3065–3076 (2022).
   PubMed Web of Science ®Google Scholar
• FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma. US FDA, MD, USA. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma (Accessed 28November2023).
   Google Scholar
• Chau I , AjaniJA , DokiYet al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648. J. Clin. Oncol.40(Suppl. 16), 4035 (2022).
   Web of Science ®Google Scholar
• Chennamadhavuni A , AbushahinL , JinN , PresleyCJ , ManneA. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front. Immunol.13, 779691 (2022).
   PubMed Web of Science ®Google Scholar
• Wu HX , PanYQ , HeYet al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J. Clin. Oncol.41, 1735–1746 (2023).
   PubMed Web of Science ®Google Scholar
• Kumagai S , KoyamaS , ItahashiKet al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell40, 201–218 (2022).
   PubMed Web of Science ®Google Scholar
• Mikuni H , YamamotoS , SawadaRet al. Correlation of combined positive score of PD-L1 expression and clinical efficacy for advanced esophageal squamous cell carcinoma treated with nivolumab monotherapy. J. Clin. Oncol.40(Suppl. 4), 289 (2022).
   Web of Science ®Google Scholar